On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the April 2026 CRG meeting. Actions in this consultation include:
- Sulfasalazine 500mg tablets, 500mg GR tablets, and 250mg.5ml oral suspension – amber (shared care) for Crohn’s disease and ulcerative colitis in patients aged 2 and older
- Ruxolitinib for vitiligo – red
- Dupilumab for COPD – red
- Fezolinetant for vasomotor symptoms of menopause – green following specialist initiation / advice
- Pegzilarginase for arginase-1 deficiency – red
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Friday 29th May 2026. To take part, visit the consultations page.
Guidelines and pathways
The following guidelines and pathways are also open for consultation:
- Primary Care Quick Reference Sheet: Acarizax® and Itulazax®
- Shared care protocol: dexamfetamine in children and adolescents
These consultations will run for six weeks and close at 5pm on Friday 29th May 2026. To take part, visit the consultations page.